vs

Side-by-side financial comparison of MEDIFAST INC (MED) and Utz Brands, Inc. (UTZ). Click either name above to swap in a different company.

Utz Brands, Inc. is the larger business by last-quarter revenue ($341.0M vs $75.1M, roughly 4.5× MEDIFAST INC). On growth, Utz Brands, Inc. posted the faster year-over-year revenue change (-3.1% vs -36.9%). Utz Brands, Inc. produced more free cash flow last quarter ($16.5M vs $-6.6M). Over the past eight quarters, Utz Brands, Inc.'s revenue compounded faster (-1.5% CAGR vs -34.4%).

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

Utz Brands, Inc., more commonly known as Utz, is an American snack food company based in Hanover, Pennsylvania. The company produces a variety of potato chips, pretzels, and other snacks, with most products sold under their family of brands. Utz is also a snack supplier to warehouse clubs and merchandisers.

MED vs UTZ — Head-to-Head

Bigger by revenue
UTZ
UTZ
4.5× larger
UTZ
$341.0M
$75.1M
MED
Growing faster (revenue YoY)
UTZ
UTZ
+33.7% gap
UTZ
-3.1%
-36.9%
MED
More free cash flow
UTZ
UTZ
$23.1M more FCF
UTZ
$16.5M
$-6.6M
MED
Faster 2-yr revenue CAGR
UTZ
UTZ
Annualised
UTZ
-1.5%
-34.4%
MED

Income Statement — Q4 2025 vs Q4 2025

Metric
MED
MED
UTZ
UTZ
Revenue
$75.1M
$341.0M
Net Profit
$2.3M
Gross Margin
69.4%
25.5%
Operating Margin
-10.4%
2.1%
Net Margin
0.7%
Revenue YoY
-36.9%
-3.1%
Net Profit YoY
108.3%
EPS (diluted)
$-1.64
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MED
MED
UTZ
UTZ
Q4 25
$75.1M
Q3 25
$89.4M
Q2 25
$105.6M
Q1 25
$115.7M
Q4 24
$119.0M
$341.0M
Q3 24
$140.2M
$365.5M
Q2 24
$168.6M
$356.2M
Q1 24
$174.7M
$346.5M
Net Profit
MED
MED
UTZ
UTZ
Q4 25
Q3 25
$-2.3M
Q2 25
$2.5M
Q1 25
$-772.0K
Q4 24
$2.3M
Q3 24
$1.1M
$-2.2M
Q2 24
$-8.2M
$19.8M
Q1 24
$8.3M
$-4.0M
Gross Margin
MED
MED
UTZ
UTZ
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
25.5%
Q3 24
75.4%
26.9%
Q2 24
73.2%
26.7%
Q1 24
72.8%
25.5%
Operating Margin
MED
MED
UTZ
UTZ
Q4 25
-10.4%
Q3 25
-4.6%
Q2 25
-1.0%
Q1 25
-1.1%
Q4 24
0.6%
2.1%
Q3 24
1.5%
5.3%
Q2 24
-4.7%
6.3%
Q1 24
4.5%
2.8%
Net Margin
MED
MED
UTZ
UTZ
Q4 25
Q3 25
-2.5%
Q2 25
2.3%
Q1 25
-0.7%
Q4 24
0.7%
Q3 24
0.8%
-0.6%
Q2 24
-4.8%
5.6%
Q1 24
4.8%
-1.2%
EPS (diluted)
MED
MED
UTZ
UTZ
Q4 25
$-1.64
Q3 25
$-0.21
Q2 25
$0.22
Q1 25
$-0.07
Q4 24
$0.08
$0.04
Q3 24
$0.10
$-0.03
Q2 24
$-0.75
$0.23
Q1 24
$0.76
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MED
MED
UTZ
UTZ
Cash + ST InvestmentsLiquidity on hand
$167.3M
$56.1M
Total DebtLower is stronger
$768.6M
Stockholders' EquityBook value
$198.9M
$696.9M
Total Assets
$248.0M
$2.7B
Debt / EquityLower = less leverage
1.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MED
MED
UTZ
UTZ
Q4 25
$167.3M
Q3 25
$173.5M
Q2 25
$162.7M
Q1 25
$164.6M
Q4 24
$162.3M
$56.1M
Q3 24
$170.0M
$64.9M
Q2 24
$163.5M
$66.6M
Q1 24
$156.4M
$47.0M
Total Debt
MED
MED
UTZ
UTZ
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$768.6M
Q3 24
$780.8M
Q2 24
$797.6M
Q1 24
$756.9M
Stockholders' Equity
MED
MED
UTZ
UTZ
Q4 25
$198.9M
Q3 25
$214.7M
Q2 25
$216.0M
Q1 25
$211.0M
Q4 24
$210.1M
$696.9M
Q3 24
$207.3M
$685.7M
Q2 24
$205.3M
$686.0M
Q1 24
$211.0M
$671.1M
Total Assets
MED
MED
UTZ
UTZ
Q4 25
$248.0M
Q3 25
$268.2M
Q2 25
$269.3M
Q1 25
$280.0M
Q4 24
$284.2M
$2.7B
Q3 24
$291.2M
$2.6B
Q2 24
$293.5M
$2.7B
Q1 24
$302.8M
$2.6B
Debt / Equity
MED
MED
UTZ
UTZ
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
1.10×
Q3 24
1.14×
Q2 24
1.16×
Q1 24
1.13×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MED
MED
UTZ
UTZ
Operating Cash FlowLast quarter
$-5.3M
$54.2M
Free Cash FlowOCF − Capex
$-6.6M
$16.5M
FCF MarginFCF / Revenue
-8.8%
4.8%
Capex IntensityCapex / Revenue
1.8%
11.1%
Cash ConversionOCF / Net Profit
23.67×
TTM Free Cash FlowTrailing 4 quarters
$1.2M
$7.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MED
MED
UTZ
UTZ
Q4 25
$-5.3M
Q3 25
$12.1M
Q2 25
$-3.4M
Q1 25
$3.4M
Q4 24
$-4.9M
$54.2M
Q3 24
$9.1M
$52.2M
Q2 24
$13.1M
$8.9M
Q1 24
$7.3M
$-9.1M
Free Cash Flow
MED
MED
UTZ
UTZ
Q4 25
$-6.6M
Q3 25
$10.8M
Q2 25
$-4.8M
Q1 25
$1.9M
Q4 24
$-7.2M
$16.5M
Q3 24
$7.7M
$29.1M
Q2 24
$11.1M
$-15.3M
Q1 24
$5.4M
$-22.7M
FCF Margin
MED
MED
UTZ
UTZ
Q4 25
-8.8%
Q3 25
12.0%
Q2 25
-4.5%
Q1 25
1.6%
Q4 24
-6.1%
4.8%
Q3 24
5.5%
8.0%
Q2 24
6.6%
-4.3%
Q1 24
3.1%
-6.5%
Capex Intensity
MED
MED
UTZ
UTZ
Q4 25
1.8%
Q3 25
1.5%
Q2 25
1.3%
Q1 25
1.3%
Q4 24
1.9%
11.1%
Q3 24
1.0%
6.3%
Q2 24
1.1%
6.8%
Q1 24
1.1%
3.9%
Cash Conversion
MED
MED
UTZ
UTZ
Q4 25
Q3 25
Q2 25
-1.36×
Q1 25
Q4 24
23.67×
Q3 24
8.04×
Q2 24
0.45×
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons